ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the successful completion of patient enrollment in its Phase II clinical study (IMM01-02), which investigates the combination of IMM01 with azacitidine for the treatment of naïve chronic myelomonocytic leukemia (CMML). The study has fully enrolled 20 patients, marking a significant milestone in the clinical development of IMM01.
Promising Initial Results with 100% Objective Response Rate
Preliminary results from the first 8 evaluable patients in the study are highly encouraging, with an objective response rate (ORR) of 100%. This includes a complete response rate (CR) of 25%, a complete bone marrow response rate of 62.5%, and a combined rate of complete bone marrow response with peripheral hematological improvement at 12.5%. These positive outcomes suggest that IMM01 in combination with azacitidine could offer a new and effective treatment option for patients with CMML.
IMM01: A Novel SIRPαFc Fusion Protein Developed by ImmuneOnco
IMM01 is the first SIRPαFc fusion protein targeting CD47 to be developed in China and was discovered and developed by ImmuneOnco utilizing its proprietary “mAb-Trap” technology platform. This innovative drug is designed to have a dual mechanism of action, which is anticipated to contribute to anti-tumor activity when used in combination with chemotherapy, targeted therapies, and immunotherapy. The potential of IMM01 to enhance the efficacy of various cancer treatments positions it as a promising candidate in the field of oncology.-Fineline Info & Tech
